TMCnet News
American Gene Technologies Inc. (AGT) CSO, David Pauza, to Present HIV Functional Cure data At The Cell & Gene Meeting on the MesaROCKVILLE, Md., Sept. 26, 2017 (GLOBE NEWSWIRE) -- American Gene Technologies International Inc. (AGT), a gene technology company focusing on a lentiviral delivery platform, today announced that Chief Science Officer C. David Pauza, Ph.D., will present at the upcoming Cell & Gene Meeting on the Mesa being held from October 4-6, 2017, in La Jolla, CA. Dr. Pauza will speak on “AGT Updates Progress to the Clinic for an HIV Functional Cure,” at 10:45 a.m. PDT on October 5, 2017. “Advances in treatment of HIV infection have enabled us to manage disease, but have not relieved the demand on patients to continue chronic therapy, suffer side effects of those treatments, and risk HIV-associated diseases including cancer,” said Dr. Pauza. “We at AGT have developed a genetic medicine treatment strategy that we believe could lead to a functional cure. My presentation will demonstrate AGT’s ability to combine the best of vector and cell product technology into a new clinical approach aimed at a functional cure for HIV disease.” Presentation material will be available after the meeting. American Gene Technologies These therapies demonstrate the breadth of AGT’s unique lentiviral platform, including such innovations as a Transient Lentivector™ for temporary expression and an ImmunoTox™ vector for stimulating anti-tumor immunity in immuno-oncology applications. More information can be found at www.americangene.com. The Cell & Gene Meeting on the Mesa AGT Contact: Media Contact: Investor Contact: |